$1M a Patient for Bandages, Then a $5M Donation

Introduction

In February 2025, a wound-care distributor called Extremity Care wired $5 million to Trump's super PAC, MAGA Inc. Six days later, Trump publicly attacked a pending Biden-era rule that would have cut Medicare payments for the exact products Extremity Care sells. CMS shelved the rule until January 2026. On June 23, the Justice Department charged 455 people in a fraud built on those same payments, including one nurse practitioner who billed Medicare more than $1 million per patient for wound bandages, some of them applied to people dying in hospice.

How Pennies of Bandage Became $1,450 a Square Centimeter

The product at the center of this is an amniotic wound allograft, a sheet of donated placental tissue that gets laid over a wound. Used on the right patient, it has real clinical value for things like diabetic foot ulcers that won't heal. What got abused wasn't the tissue, it was the price, and the fact that the seller got to set it.

Medicare reimburses these products under a formula called ASP plus 6 percent. The agency pays 106 percent of the "average sales price" the company reports for its own product. There's no independent appraisal. A company that doesn't manufacture anything can buy a sheet of tissue from a tissue bank for a small amount, slap a new label on it, declare that its average sales price is $1,450 per square centimeter, and Medicare pays based on that number. The Justice Department press release describes one company doing exactly that, marking the tissue up by 2,000 percent over what it paid the bank.

Once the price was set absurdly high, the spread funded the whole scheme. The company took roughly 40 percent of that inflated price, somewhere around $500 to $600 per square centimeter, and kicked it back to the sales reps and providers who agreed to order it. A higher reported price meant a bigger kickback, which moved more product, so nobody in the chain had any reason to ask whether the patient needed a graft and plenty of reason to make sure a large one got applied. Skin substitute spending under Medicare Part B went from $256 million in 2019 to more than $10 billion in 2024, according to CMS. That's a 39-fold jump in five years, which is what a worked loophole looks like.

The People Who Got Paid, and the Patients Who Got Grafted

Start with the case that already closed. Alexandra Gehrke and Jeffrey King, who ran a network of marketing companies including Apex Medical and Viking Medical Consultants, were sentenced in October 2025 to 15.5 and 14 years. Over 18 months they submitted $1,212,005,778 in false claims. Gehrke personally took more than $279 million in kickbacks from the wholesale distributor that supplied the grafts; King's company took another $130 million. The government's filing describes what they ordered their people to do: apply grafts to non-existent wounds, apply them to terminally ill patients in palliative care, some of whom died within days or the same day, and instruct the nurse practitioners to "suspend their medical judgment" and order only the largest graft sizes available, because a larger graft meant a larger bill.

The charges announced on June 23 extend that same machine. Brian Rowan, 47, the VP of sales for the company at the center of the new indictment, is charged in connection with a $1.2 billion scheme, roughly $614 million of it paid. The case summaries say he personally received over $24 million, which went to multi-million-dollar houses, life insurance policies, watches, and a $135,000 Maserati. His method, per the filing: sham invoices sent to providers for more than they actually paid, so the providers could bill Medicare off the inflated number and pocket the gap. Across that whole company, not just Rowan's charged slice, providers billed Medicare more than $4 billion over two and a half years and Medicare paid more than $2 billion.

Then there's Marizel Yukee, the nurse practitioner charged in a $906 million scheme run through four mobile wound clinics. According to the press release, she billed Medicare more than $1 million per patient on average. Investigators seized over $30 million from her accounts, a $594,000 Ferrari, an $865,000 custom Bulgari necklace, and traced $4.6 million to a beach resort in the Philippines. Every defendant here is presumed innocent, and these are charging documents, not convictions. But the dollar figures come straight from the government's own filings.

The number that should land hardest is the one CMS put in its premium fact sheet: if the administration hadn't acted on skin substitute spending, the 2026 Part B premium increase would have been about $11 more a month for every beneficiary. With roughly 64 million people on Medicare, that's the cost of this scheme showing up directly on the bill of everyone in the program, whether or not they ever saw a wound graft.

The Other Side of the Same Ledger

Here's the part that stuck with me. While traditional Medicare was paying up to $1,450 a square centimeter for bandages on dying patients with no medical review, the same program's largest insurers were telling seniors who actually needed care to wait.

An OIG report from June 2026 looked at how Medicare Advantage plans handled prior authorization for inpatient rehab, the kind of care someone needs after a stroke. UnitedHealthcare denied 66 percent of those requests. Humana denied 54 percent, CVS 51 percent. When patients appealed, insurers reversed more than a third of the denials, which is the OIG's polite way of saying a lot of that care was medically necessary and got refused anyway. An inpatient rehab stay runs about $24,000, and that figure was worth a prior-authorization fight. A salesperson with no medical training applying adhesive tissue to dying patients apparently wasn't.

Medicare built rigorous gates in front of the care seniors are entitled to and left the back door wide open for anyone willing to report a high enough price. The fraud succeeded for years because the rules were written to pay first and ask questions later, if at all, which meant the criminals never had to outsmart anything; they just had to bill.

Who Benefits

The money beneficiaries are easy to name because the government already named them. Distributor executives like Rowan ($24 million), marketing operators like Gehrke ($279 million) and King ($130 million), and nurse practitioners like Yukee, who took roughly $16 million in kickbacks. The mechanism was the ASP spread: report a high price, collect 106 percent of it from Medicare, kick back 40 percent to whoever placed the order. Everyone in the chain made money on volume, and the patient was just the body the graft got applied to.

But there's a beneficiary layer the criminal charges don't reach, and it's the one that explains why this ran as long as it did. The distributor identified in New York Times and Fierce Healthcare reporting as the upstream supplier in this space, Extremity Care, donated $5 million to MAGA Inc. on February 24, 2025. According to Popular Information, which found the donation in MAGA Inc.'s FEC mid-year report, Trump attacked the pending Biden rule restricting coverage of these products six days later. CMS then delayed that rule until at least January 1, 2026. Extremity Care also quietly gave $2.5 million toward the White House ballroom project, which donors were permitted to fund anonymously.

The donation is legal. The timing is documented in public records, and the causation is circumstantial, a correlation in dates, not a proven quid pro quo. Extremity Care has not been charged with anything, and the company named in the reporting, Legacy Medical Consultants, denies wrongdoing; its CEO says it never paid illegal kickbacks and calls its rebate programs lawful practice "encouraged by CMS." Hold all of that. What the public filings show is this: the distributor at the center of a product category Medicare was hemorrhaging money on wrote an eight-figure check to the administration's PAC, and within a week the administration moved against the rule that would have cut the spending. The delay let the inflated payments run for nearly another year before the cut took effect.

What the Victory Lap Skips

The standard story here is that the system worked. CMS flagged the problem, cut the rate to $127 per square centimeter starting January 1, 2026, and projects $19.6 billion in savings this year, a drop of nearly 90 percent. DOJ's data analytics caught the billing spike and built the prosecutions. The administration is taking a victory lap on all of it.

Most of that is true. The cut is real and the savings are real. But the victory lap skips a chapter. The rule that would have curbed this spending earlier was a Biden-era coverage restriction, and it didn't quietly expire on its own. It got attacked by the same administration now claiming credit, a week after the $5 million donation documented above, and then delayed for nine months. The OIG had already warned in September 2025 that skin substitutes were "particularly vulnerable to questionable billing and fraud schemes," that home-treated patients were costing four times what office patients did, and that manufacturer price reporting had gaps the agency couldn't independently verify. The warning was on the record and the fix was already drafted. Both sat on a shelf while the spending compounded.

So when you read that the government shut down a $6.5 billion fraud, the honest version is that the government shut down a fraud it had the tools to slow earlier and chose, for at least a year, not to. The same payment formula that made the scheme possible, ASP plus 6 percent with no independent price check, is still the formula. CMS lowered the number this time around, but the company still gets to set it.

The Bottom Line

The 455 charges and the seized Ferraris will get the headlines, and they should, because the conduct is genuinely grotesque. But the structural part is what outlasts them. Medicare paid more than $1 million per patient for bandages on dying people because its rules were built to pay whatever a company claimed its product was worth, and when a fix came up, a documented donation preceded a year-long delay that kept the money flowing.

The rate dropped to $127 a square centimeter. The 60-plus million people who paid higher premiums during the years it ran don't get that back, and the formula that let a company name its own price is still on the books for the next product. The open question is which one, and how long the warning sits on a shelf next time.